Ragini Reiney Kudchadkar

机构：Emory University, Piedmont Cancer Institute · ORCID：0000-0001-9070-5052

发表论文 235 篇 · 总被引 17156 次 · h-index 54

代表论文

• Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. (2025 · Journal of Clinical Oncology · 被引 47)
• FcγRIIB expressed on CD8+T cells limits responsiveness to PD-1 checkpoint inhibition in cancer (2023 · Science Translational Medicine · 被引 22)
• Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry (2022 · PLoS ONE · 被引 19)
• HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors (2025 · Future Oncology · 被引 12)
• Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma (2022 · Journal for ImmunoTherapy of Cancer · 被引 9)
• A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease (2022 · JCR Journal of Clinical Rheumatology · 被引 8)